Clinical Trial Update: Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating gecacitinib before, during, and after hematopoietic stem cell transplantation in patients with primary or secondary myelofibro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• Gecacitinib (Gecacitinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Myelofibrosis (MF), HSCT | Phase 2 | Status: NOT_YET_RECRUITING